[{"id":"4b28cba1-eb2a-4ca5-a108-23c6f9985947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05145179","created_at":"2021-12-07T00:58:59.480Z","updated_at":"2024-07-02T16:36:19.851Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors","source_id_and_acronym":"NCT05145179","lead_sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSGJ-705"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-12-06"}]